YETI Holdings (NYSE:YETI) Stock, Quote.Headers.trade-ideas

YETI Holdings

YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.

xr:d:DAFnlkPxbGw:2,j:2301734779993818017,t:23070314

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLD

DOYU

NEGG

RERE

YETI

Li Auto Posts Weak Q1 Results, Joins ATRenew And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Wall Street US stocks

Intraday Update

ABNB

AIXI

ALGM

ALTG

ARGX

ASLE

BIGC

BLBD

BNED

BYND

CAMT

CCSI

CDLX

COMP

CPOP

CRNC

CTMX

DUOL

EMBC

EMKR

EPAM

EQIX

EXAS

FWRD

GLOB

GWAV

IHRT

IRWD

KVYO

LFMD

MGNI

PENN

PLTK

PYCR

RAPT

RBLX

SBGI

SEDG

SEZL

SITM

SKYT

STVN

SYRA

TIVC

TIXT

VITL

WRBY

ZIMV

ZLAB

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

xr:d:DAFirWODRGc:2,j:4528549651,t:23051205

ICUI

PAAS

PRMW

USFD

Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday

YETI Holdings Inc

<p><strong>Deepwater Asset Management&#8217;s</strong> managing partners, <strong>Gene Munster</strong> and <strong>Doug Clinton</strong> have <a href="https://www.businessinsider.in/tech/news/openais-new-searchgpt-prototype-is-a-declaration-of-war-against-google/articleshow/112024630.cms">downplayed concerns</a> that <strong>Alphabet Inc.&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) <strong>Google Search</strong> could be outdone by <strong>OpenAI&#8217;s SearchGPT</strong>.</p>
<p><strong>What Happened</strong>: On Friday, Munster took to <strong>X</strong>, formerly <strong>Twitter</strong>, and said, &#8220;Since it&#8217;s only a 15-second video, it&#8217;s hard to see why SearchGPT is 10x better than Google AI Overviews.&#8221;</p>
<p>He went on to say that in the near term, this revives fears among Google investors that AI could threaten search. However, if the product&#8217;s capabilities are limited to what&#8217;s shown in the teaser, Google is not in any significant danger.</p>
<p><strong>See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39922283/elon-musk-is-polling-x-and-asking-if-tesla-should-invest-5b-in-grok-parent-xai-this-is-just-to-test?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Is Polling X And Asking If Tesla Should Invest $5B In Grok Parent xAI: &#8216;This Is Just To Test The Waters&#8217;</a></strong></p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Since its only a 15 second video, it&#39;s hard to see why SearchGPT is 10x better than Google AI Overviews.  <br /><br />Near-term this revive fears from <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> investors that AI can kill search. <br /><br />If this is the product, Google is not in any meaningful danger. <a href="https://t.co/YX4Qa4Smac">https://t.co/YX4Qa4Smac</a></p>
<p>&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816549429782151403?ref_src=twsrc%5Etfw">July 25, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Doug Clinton</strong>, the other managing partner at Deepwater, concurred with Munster&#8217;s views. He said that although the SearchGPT video resulted in a minor dip in Google&#8217;s stock, it does not pose a substantial threat to Google&#8217;s AI.</p>
<p>&#8220;It didn&#8217;t seem 10x superior to what I&#8217;m observing&nbsp;from Google and AI overviews,&#8221; Clinton remarked in a separate video.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">On this week&#39;s DeepTech315, <a href="https://twitter.com/dougclinton?ref_src=twsrc%5Etfw">@dougclinton</a> and I discuss <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> and <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a> earnings, and OpenAI&#39;s new search product, SearchGPT. <a href="https://t.co/9cGt75OwAu">pic.twitter.com/9cGt75OwAu</a></p>
<p>&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1816565516309295351?ref_src=twsrc%5Etfw">July 25, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Both partners concurred that unless SearchGPT can offer something unique or more than what was shown in the teaser, it&#8217;s difficult to see why users would switch from Google.</p>
<p><em>Subscribe to the&nbsp;</em><a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener"><em>Benzinga Tech Trends newsletter</em></a><em>&nbsp;to get all the latest tech developments delivered to your inbox.</em></p>
<p><strong>Why It Matters</strong>: On Thursday, Alphabet shares were trading lower after a <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know">report suggested that OpenAI plans</a> to launch an online search tool called &#8220;SearchGPT&#8221; to disrupt Google's Search dominance.</p>
<p>Soon after, <strong>ChatGPT</strong>-parent, announced that it is testing SearchGPT, a temporary prototype of new AI search features. The launch is initially limited to a small group of users for feedback, with plans to integrate the experience into ChatGPT, the company stated.</p>
<p><strong>Price Action: </strong>At the time of writing, Alphabet's Class A shares were down by 0.072% in after-hours trading to $166.88, while Class C shares dropped 0.018% to $168.65. During the regular session, Class A and Class C shares had closed at $167 and $168.68, respectively, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">&nbsp;Benzinga Pro data</a>.</p>
<p><em>Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;</em><a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener"><em>following this link</em></a><em>.</em></p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/07/39929189/elon-musk-agrees-with-mark-zuckerberg-on-apple-tesla-ceo-wonders-how-many-enemies-he-can-make-and-su?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees With Mark Zuckerberg On Apple, Tesla CEO Wonders How Many Enemies He Can Make And Survive</a></strong></li>
</ul>
<p><strong><em>Disclaimer:</em></strong><em>&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Google Photo by DenPhotos on Shutterstock</em></p>


Tech

General

GOOG

GOOGL

Top Analyst Says OpenAI's AI-Powered Search Engine Likely Isn't A Threat To Google: 'It's Hard To See Why SearchGPT Is 10X Better…'

<p>The much-anticipated initial public offering (IPO) of billionaire investor <strong>Bill Ackman</strong>&#8216;s Pershing Square closed-end fund has been postponed, as confirmed by the New York Stock Exchange (NYSE.)</p>
<p><strong>What Happened</strong>: On Friday, the NYSE announced on its website that the listing of <strong>Pershing Square USA Ltd.</strong> has been delayed, with a new date yet to be disclosed. </p>
<p>Pershing Square refrained from commenting further but issued a statement clarifying that the IPO is still proceeding, with the pricing date to be announced later.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/24/07/39947623/lindsey-graham-says-americans-are-struggling-and-our-country-is-heading-in-the-wrong-direction-repla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lindsey Graham Says &#8216;Americans Are Struggling, And Our Country Is Heading In The Wrong Direction&#8217;</a></strong></p>
<p>The delay comes amid Ackman&#8217;s concerns about the size of the transaction and the novelty of the structure. He expressed these concerns in a July 24 letter to investors, emphasizing the need for careful analysis and judgment from investors.</p>
<p>The fund is expected to invest in 12 to 24 large-cap, investment-grade, &#8220;durable growth&#8221; companies in North America. The public listing is seen as a move to leverage Ackman&#8217;s following among Main Street investors.</p>
<p><strong>Why It Matters</strong>: The IPO delay follows a <a href="https://www.benzinga.com/news/24/07/39975768/bill-ackmans-us-fund-ipo-target-slashed-by-90-as-pershing-square-specifically-disclaims-ceos-comment">significant reduction in the fund&#8217;s targe</a>t, which was slashed by as much as 90% from the initial $25 billion. In a letter to investors in his Pershing Square holding company sent on Wednesday, Ackman urged, "This is a moment when you can be very helpful to Pershing Square by participating in the PSUS offering and giving your order to the banks, the sooner the better." However, Pershing Square USA "specifically disclaims" Ackman's statement in the filing that included the letter.</p>
<p>Inspired by <strong>Warren Buffett</strong>&#8216;s career, <a href="https://www.benzinga.com/news/24/07/39766570/bill-ackman-says-his-unofficial-mentor-warren-buffett-inspired-him-to-take-pershing-square-funds-pub">Ackman decided to take his funds public.</a> He planned to use his social media presence and a Buffett-like annual meeting to bolster his new investment fund.</p>
<p>Pershing Square USA is a closed-end fund set to be listed on the New York Stock Exchange, investing in large, publicly traded stocks that Ackman and his team believe are undervalued. Ackman had previously informed investors that he expected the company to trade at a premium compared to the net assets it held.</p>
<p>Despite the reduction in the IPO target, Ackman remains optimistic about the fund's potential, particularly with the involvement of U.S. retail investors and the&nbsp;<a href="https://www.benzinga.com/news/24/07/39811552/from-warren-buffett-style-annual-meetings-to-social-media-strategy-heres-how-bill-ackman-plans-to-bo" target="_blank" rel="noreferrer noopener">support of institutional investors</a>.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cannabis/24/07/39964922/ron-desantis-says-florida-supreme-court-should-not-have-allowed-cannabis-legalization-initiative?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ron DeSantis Says Florida Supreme Court Should &#8216;Not Have Allowed&#8217; Cannabis Legalization Initiative On Ballot</a></strong></li>
</ul>
<p><em>This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image via Harvard Association for Law and Business/ Tracy Tolf</em></p>


IPOs

Bill Ackman's Warren Buffett-Inspired Strategy Hits A Snag? Pershing Square USA Delays IPO Indefinitely After Slashing Target By 90%

<p>US Treasury Secretary<strong> Janet Yellen</strong> has strongly refuted allegations of manipulating the issuance of <a href="https://www.benzinga.com/topic/treasuries">Treasury securities</a>. These accusations were made by economist <strong>Nouriel Roubini</strong> who suggested that such manipulation was aimed at reducing real borrowing costs across the economy.</p>
<p><strong>What Happened:</strong> Yellen dismissed Roubini&#8217;s argument that the Treasury had a strategy to ease financial conditions, in an <a href="https://www.bloomberg.com/news/articles/2024-07-26/yellen-rejects-roubini-claim-of-manipulation-in-treasuries">interview</a> with Bloomberg.</p>
<p>&#8220;I can assure you 100% that there is no such strategy. We have never, ever discussed anything of the sort,&#8221; Yellen said.</p>
<p>The paper, co-authored by Roubini and <strong>Stephen Miran</strong>, a former Treasury official under President <strong>Donald Trump</strong>, claimed that the Treasury&#8217;s actions in the fall of last year reduced 10-year Treasury yields by a quarter of a percentage point.</p>
<p>This is roughly equivalent to a full percentage point reduction in the Federal Reserve&#8217;s benchmark rate.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39948413/trump-era-white-house-official-anthony-scaramucci-says-kamala-harris-is-capable-and-has-a-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Era White House Official Anthony Scaramucci Says Kamala Harris Is Capable And Has A Great Team</a></strong></p>
<p><strong>Joshua Frost</strong>, the Treasury&#8217;s assistant secretary for financial markets, defended the department&#8217;s actions, stating they were within market participants&#8217; expectations.</p>
<p>Yellen supported Frost&#8217;s statements, saying his speech provided the best explanation for the department&#8217;s approach.</p>
<p><strong>Why It Matters:</strong> The allegations against Yellen come in the wake of a series of events that have put her in the spotlight.</p>
<p>Earlier this month, <a href="https://www.benzinga.com/government/24/07/39749545/trump-allies-slam-janet-yellen-for-manipulating-treasury-debt-auctions-to-improve-bidens-image">she was accused</a> by Republican lawmakers of manipulating Treasury debt auctions to stimulate the economy and enhance President <strong>Joe Biden‘s</strong> image. This latest development is a continuation of the scrutiny Yellen has been facing.</p>
<p><a href="https://www.benzinga.com/government/24/05/38572650/janet-yellen-stands-up-for-feds-autonomy-as-trump-allies-plan-to-gain-more-control">Yellen also defended</a> the Federal Reserve&#8217;s political independence against attempts by Trump allies to undermine it.</p>
<p>In June, she <a href="https://www.benzinga.com/news/24/06/39348581/janet-yellen-dismisses-donald-trumps-proposal-to-replace-income-tax-with-tariffs-the-impact-would-be">publicly criticized Trump&#8217;s proposal</a> to replace parts of the U.S. income tax with increased tariffs on imported goods.</p>
<p>Later that month, she <a href="https://www.benzinga.com/government/24/06/39470021/janet-yellen-says-inflation-to-come-down-to-feds-2-target-by-2025-dismisses-possibility-of-us-recess">expressed confidence</a> in the American economy, dismissing the possibility of a recession and predicting that inflation would reach the Federal Reserve's 2% target by next year.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/politics/24/07/39992709/kamala-harris-will-certify-2024-election-results-shes-not-going-to-burn-the-system-down-in-order?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kamala Harris Will Certify 2024 Election Results: &#8216;She&#8217;s Not Going To Burn The System Down In Order To Save It'</a></strong></li>
</ul>
<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Photo courtesy: Flickr</em></p>


Treasuries

Economics

Janet Yellen Rejects Economist Roubini's And Trump-Era Official's Claims Of 'Manipulation' In Treasuries: 'We Have Never, Ever Discussed Anything Of The Sort'

<p><strong>Alphabet Inc.'s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) <strong>Google</strong> has severed its business ties with One Medical, a <a href="https://www.benzinga.com/topic/healthcare">primary healthcare provider</a> acquired by <strong>Amazon.com Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for $3.9 billion.</p>
<p><strong>What Happened</strong>: Google, previously One Medical&#8217;s largest business client, has decided to terminate its enterprise agreement with the healthcare company following Amazon&#8217;s acquisition of One Medical last year, <a href="https://www.businessinsider.com/google-drops-amazon-one-medical-2024-7">reported</a> Business Insider.</p>
<p>The agreement, which offered Google employees discounted or free One Medical memberships and operated One Medical care centers at some Google office locations, is set to expire at the end of 2024.</p>
<p>Google was an early supporter of One Medical and was its largest business customer for many years. Until 2020, One Medical disclosed that Google accounted for 10% of its net revenue.</p>
<p>In 2021, that dipped below 10%, and then One Medical stopped publicly sharing financials after Amazon acquired it.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/biotech/24/07/39940874/gileads-42-5k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Gilead&#8217;s $42.5K Priced HIV Drug Could Be Made At Just $40 Annually</a></strong></p>
<p>A Google spokesperson confirmed to the publication that the existing relationship with One Medical is changing after 2024 but stressed that the decision has nothing to do with Amazon&#8217;s new ownership of the healthcare provider.</p>
<p>The existing One Medical centers on Google&#8217;s campus have already transitioned to Premise Health to provide more services like pharmacy, gynecology, and coordinated care on-site, the spokesperson added.</p>
<p>An Amazon spokesperson told Business Insider that Google employees and their dependents will continue to have One Medical memberships &#8220;sponsored&#8221; by their employer through the end of 2024.</p>
<p><strong>Why It Matters</strong>: The termination of Google&#8217;s business relationship with One Medical comes amid significant changes within the healthcare provider.</p>
<p>In September, CEO <strong>Amir Dan Rubin</strong> <a href="https://www.benzinga.com/news/23/09/34166966/amazons-one-medical-ceo-departs-amid-significant-leadership-shift">stepped down</a> from One Medical after six years at the helm, a little over a year after Amazon&#8217;s acquisition.</p>
<p>This leadership shift was followed by <a href="https://www.benzinga.com/general/biotech/24/02/36971965/amazon-implements-major-job-cuts-in-one-medical-and-pharmacy-units-to-save-100m">major job cuts</a> in February, as part of a cost-saving initiative aiming to save One Medical $100 million.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/07/39954971/apple-drops-from-3rd-to-6th-in-china-amid-intensifying-competition-huawei-shipments-surge-41-in-">Apple Drops From 3rd To 6th In China Amid Intensifying Competition, Huawei Shipments Surge 41% In Q2: Report</a></strong></li>
</ul>
<p><strong><em>Disclaimer:</em></strong><em>&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Photo courtesy: Amazon</em></p>


Health Care

AMZN

Google Cuts Ties With Amazon-Owned One Medical, But Clarifies It Is Not Due To E-Commerce Giant's $3.9B Acquisition

<p>Following President <strong>Joe Biden&#8217;s</strong> decision to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885549/biden-withdraws-from-2024-race-what-that-means-for-solana-etf-prospects">withdraw from the 2024 presidential race</a>, a poll conducted by The Wall Street Journal indicates that former President <strong>Donald Trump</strong> has a slight edge over Vice President <strong>Kamala Harris</strong>.</p>
<p><strong>What Happened</strong>: The poll <a href="https://www.wsj.com/politics/elections/harris-erases-trumps-lead-wsj-poll-finds-e286144d?mod=e2tw">results</a> published on Friday revealed that Trump has the support of 49% of registered voters, while Harris trails slightly behind with 47%. The WSJ poll, conducted from July 23-25, surveyed 1,000 registered voters with a margin of error&nbsp;of ±3.1 percentage points.</p>
<p>The latest poll also showed a significant rise in Harris&#8217;s favorability among registered voters, jumping 11 points to 46%. In comparison, Trump&#8217;s favorability was at 47% and Biden&#8217;s at 39%.</p>
<p><strong>See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un Rejects Donald Trump&#8217;s Friendship Claims? North Korea Says &#8216;We Do Not Care,&#8217; Expresses Nuclear Readiness Amid Rising Tension With US</a></strong></p>
<p>In a ballot test featuring<strong> Robert F. Kennedy Jr.</strong> alongside other independent and third-party candidates, Harris secured 45% of the vote, while Trump received 44%. Kennedy garnered just 4%, and 5% of voters remained undecided. </p>
<p>In the last poll, Biden trailed by six points in the multicandidate contest, the report noted.</p>
<p><strong>Why It Matters</strong>: The&nbsp;<a href="https://www.benzinga.com/general/politics/24/07/39973800/trump-vs-harris-vice-president-gains-ground-lost-by-joe-biden-in-swing-states">race between Trump and Harris</a>&nbsp;is shaping up to be a close one, with Harris making up ground lost by Biden in head-to-head matchups against Trump. </p>
<p>President Biden&#8217;s campaign was plagued by a lackluster debate performance and concerns about his age and mental fitness, leading to his withdrawal last week.</p>
<p>Since Biden&#8217;s exit, Harris has garnered several key endorsements from her party, experienced a surge in fundraising, and secured enough delegate commitments to secure the nomination.</p>
<p>Meanwhile, Trump has been&nbsp;<a href="https://www.benzinga.com/news/24/07/39947274/trump-takes-aim-at-kamala-harris-in-first-rally-post-bidens-exit-calls-her-a-radical-left-lunatic-vp">criticizing Harris</a>&nbsp;on immigration and inflation issues, labeling her as a &#8220;radical-left lunatic.&#8221;</p>
<p>There has also been speculation about whether Trump might&nbsp;<a href="https://www.benzinga.com/news/24/07/39979544/can-trump-replace-jd-vance-amid-kamala-harris-picking-pace-experts-warn-that-could-be-extraordinaril">replace his vice presidential candidate</a>, Sen. <strong>J.D. Vance</strong>, due to the latter&#8217;s underwhelming polling and Harris&#8217;s growing momentum. </p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/07/39975168/nikki-haley-says-democrats-are-very-smart-to-put-in-a-younger-candidate-against-trump-but-kamala-har?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nikki Haley Says &#8216;Democrats Are Very Smart To Put In A Younger Candidate&#8217; Against Trump But Kamala Harris Is The &#8216;Weakest Candidate&#8217;</a></strong></li>
</ul>
<p><strong><em>Disclaimer:</em></strong><em>&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image Via Shutterstock</em></p>


Politics

Media

Trump Vs. Harris: New Poll Shows Ex-President Leading Democratic Candidate By A Narrow Margin, But Vice President's Favorability Is Faring Better Than Biden

<p>H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. </p>
<p><strong>Buying $1000 In HRB:</strong> If an investor had bought $1000 of HRB stock 5 years ago, it would be worth <strong>$2,049.30</strong> today based on a price of $56.95 for HRB at the time of writing.</p>
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. </p>
<p><strong>Buying $1000 In APO:</strong> If an investor had bought $1000 of APO stock 10 years ago, it would be worth <strong>$4,546.33</strong> today based on a price of $122.16 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

<p>Citigroup  analyst Atif Malik   maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.</p>


Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

<p>During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Puma Biotechnology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Puma Biotechnology</h2>
<p>Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.</p>
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Challenges:</strong> Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-17.07%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-11.0%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-9.22%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Puma Biotechnology's ROA excels beyond industry benchmarks, reaching <strong>-2.17%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.17</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PBYI

Where Puma Biotechnology Stands With Analysts

<p>During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lennox Intl analyst ratings.</strong></a></p>
<h2>Delving into Lennox Intl's Background</h2>
<p>Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.</p>
<h3>Unraveling the Financial Story of Lennox Intl</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of <strong>2.81%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.95%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>51.98%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.92%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.72</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


10 Analysts Have This To Say About Lennox Intl

<p>Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. </p>
<p><strong>Buying $1000 In TSM:</strong> If an investor had bought $1000 of TSM stock 10 years ago, it would be worth <strong>$7,815.64</strong> today based on a price of $161.40 for TSM at the time of writing.</p>
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

<p>Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. </p>
<p><strong>Buying $100 In CNQ:</strong> If an investor had bought $100 of CNQ stock 5 years ago, it would be worth <strong>$279.38</strong> today based on a price of $34.42 for CNQ at the time of writing.</p>
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Betterware de Mexico SAPI analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
<p>Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.</p>
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>10.36%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.16%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>19.7%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.68%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>3.6</strong>, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

<p>Canaccord Genuity  analyst Dalton Baretto   maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.</p>


TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

<p>Canaccord Genuity  analyst Mike Mueller   maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.</p>


TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

<p>First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.</p>


Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

<p><strong>PayPal Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has <strong>20.55 million shares sold short</strong>, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.04 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

<p><strong>Owens-Corning's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has <strong>1.49 million shares sold short</strong>, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.27 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Owens-Corning's Recent Short Interest

<p><strong>Kohl's's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has <strong>40.73 million shares sold short</strong>, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 8.49 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(KSS) - Analyzing Kohl's's Short Interest

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Yeti Holdings (YETI – Research Report), Hilton Grand Vacat...

Analysts' Opinions Are Mixed on These Consumer Cyclical Stocks: Yeti Holdings (YETI), Hilton Grand Vacations (HGV) and Berry Global Group (BERY)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>If you&rsquo;re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual <strong>S&amp;P 500 </strong>return is approximately 10%. At that rate the law of 72 states that an investor can expect their capital to double roughly every 7 years.&nbsp;</p>



<p>Thus, those seeking 100% returns by 2025 will have to take some risks. There is effectively zero chance that an average strategy will double an investor&rsquo;s returns within that time frame. That doesn&rsquo;t mean an investor should place 100% of their capital in Risky stocks such as those discussed below. Instead, a more pragmatic approach limiting exposure to the neighborhood of 10% is prudent.</p>



<p>In that way an investor can achieve annual returns above that aforementioned 10% threshold while limiting downside exposure. Let&rsquo;s learn about a handful of stocks that make sense in that regard.</p>



<h2>Stocks to Buy: Arrowhead Pharmaceuticals (ARWR)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/arwr-stock-1-300x169.jpg" alt="Image of the Arrowhead Pharmaceuticals (ARWR) website with a magnifying glass focusing on the logo"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Arrowhead Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/arwr-stock-quote/"><strong>ARWR</strong></a></span>) is a relatively well-established pharmaceutical stock with a deep pipeline of drugs representing current and future potential.&nbsp;&nbsp;</p>



<p>Investors should note that its current price of $24 suggests overall stability. It&rsquo;s very easy to find pharma <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> trading in the under $10 range that offer double and triple return potential. It&rsquo;s much more difficult to find a more established choice like Arrowhead Pharmaceuticals <a href="https://stockanalysis.com/stocks/arwr/forecast/">offering similar upside</a>.</p>



<p>The reason Arrowhead Pharmaceuticals is much more stable relates to the current progress within its pipeline. The company has <a href="https://arrowheadpharma.com/pipeline/">multiple drugs within phase 3 testing</a> at the moment. The company is on the cusp of becoming a leading pharma firm in the cardiometabolic niche.</p>



<p>Beyond that, the company offers a lot of potential in regard to its treatments for non-alcoholic steatohepatitis (NASH). It has 2 NASH treatments, one licensed to <strong>GSK</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/gsk-stock-quote/"><strong>GSK</strong></a></span>) and the other remaining unlicensed. What&rsquo;s important to note here is that NASH treatments are being studied for their weight loss efficacy as well. Therapeutics that induce weight loss while also curing a secondary issue are more likely to be covered by insurance. That gives them greater revenue potential overall and is an excellent reason to consider Arrowhead Pharmaceuticals.</p>



<h2>YETI (YETI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/yeti_yeti1600-300x169.jpg" alt="Several thermoses with the Yeti logo on them"><div>Source: David Tonelson / Shutterstock.com</div></div><p><strong>YETI</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/yeti-stock-quote/"><strong>YETI</strong></a></span>) is the outdoor brand made famous for its tumblers, coolers, and other camping goods. Its stock is also one to consider for investors chasing 100% gains by 2025. Those <a href="https://stockanalysis.com/stocks/yeti/forecast/">levels of return are entirely possible </a>at this point, even after the company jumped higher following <a href="https://www.businesswire.com/news/home/20240509230705/en/YETI-Reports-First-Quarter-2024-Results/">strong earnings</a>.&nbsp;</p>



<p>Sales increased by 13% overall in the first quarter. That strong growth was underpinned by particularly strong sales in outdoor equipment and within the firm&rsquo;s international segment where sales spiked by 32%.&nbsp;</p>



<p>Earnings increased by 50%, rising to 18 cents. Meanwhile, the company entered into A share repurchase program valued at $100 million. The company witnessed double-digit growth across all of its segments. YETI stock currently trades for just under $40. The consensus view is that those shares will rise to $85 in the next year or so. The high analyst forecast suggests that share prices could rise as high as $600. Sales are expected to continue increasing near the double digit range and YETI stock is poised for further growth.&nbsp;</p>



<h2>Stocks to Buy: NovoCure Limited (NVCR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/shutterstock_2026542092-300x169.jpg" alt="NVCR stock: Novocure limited logo is seen on a mobile phone and a computer screen."><div>Source: viewimage / Shutterstock</div></div><p><strong>NovoCure Limited</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvcr-stock-quote/"><strong>NVCR</strong></a></span>) is an oncology company working to extend survival in more aggressive forms of cancer. The company has multiple revenue streams, differentiating it from many other high potential pre-revenue pharma stocks.</p>



<p>The company <a href="https://www.novocure.com/novocure-reports-first-quarter-2024-financial-results/">reported 3,845 patients actively receiving its therapies</a> as of March 31. That resulted in overall revenues of $138.5 million during the period, up 13%. NovoCure Limited&rsquo;s operating and net income losses continue to narrow.</p>



<p>The company is interesting as an investment because it has greater potential moving forward. The company has multiple Phase 3 trials ongoing. So, the company clearly has potential to increase its revenue streams in number.&nbsp;&nbsp;</p>



<p>NovoCure Limited is also interesting in relation to a treatment modality known as tumor treating fields. Tumor treating fields utilize alternating electric fields of differing frequency to treat tumors. The company continues to work to commercialize tumor treating fields modalities offering further upside for investors to consider.</p>



<h2>Joby Aviation (JOBY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/11/joby1600-2-300x169.png" alt="Smartphone with logo of American eVTOL company Joby Aviation on screen in front of business website. Focus on center-left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Joby Aviation </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/joby-stock-quote/"><strong>JOBY</strong></a></span>) continues to be the best choice among <a href="https://investorplace.com/industries/consumer-discretionary/automotive/flying-cars/">flying car stocks</a>. The company <a href="https://ir.jobyaviation.com/news-events/press-releases/detail/96/joby-reports-first-quarter-2024-results">recently reported earnings</a> that included an EPS beat. However, that is not the only reason to consider Joby Aviation to be the best of the flying car opportunities.</p>



<p>Investors should also consider that the company is the only one to have its electric air taxi service final airworthiness criteria published by the FAA.&nbsp;</p>



<p>Joby Aviation is scheduled to deliver two aircraft to MacDill Air Base in 2025. Thus, the company continues to improve its relationship with the military. The company clearly has a massive opportunity there.</p>



<p>Beyond that, Joby Aviation also has an excellent opportunity internationally. The company continues to bolster its relationship with the United Arab Emirates. It has exclusive rights to operate air taxis in Dubai and also recently signed agreements to bring air taxis to the Abu Dhabi Emirate as well. Although flying car stocks have largely declined in 2024, Joby Aviation has fared better than most. It continues to show more promise than its competitors and is, in my opinion, the best choice overall, making it one of those stocks to buy now.</p>



<h2>Stocks to Buy: Viking Therapeutics (VKTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png" alt="Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock"><div>Source: Hernan E. Schmidt / Shutterstock.com</div></div><p><strong>Viking Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vktx-stock-quote/"><strong>VKTX</strong></a></span>) has emerged as one of the biggest challengers in the weight loss pharma stock segment. It has also skyrocketed in 2024, having increased in value by more than 300%. Shares now trade for $80 and have a chance to double, though slim.</p>



<p>Investors should pay particular attention to the company&rsquo;s VK2809 therapeutic. The drug is <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-update-302126602.html">currently in Phase 2b clinical trials</a> for the treatment of non-alcoholic steatohepatitis (NASH).&nbsp;</p>



<p>Many firms developing therapeutics for NASH are particularly promising. Drugs that can reduce the effects of that disease are also proving highly effective at inducing weight loss.</p>



<p>That means those companies including Viking Therapeutics are well positioned as weight loss drugs continue to be commercialized. What&rsquo;s more, therapeutics that have secondary indications are those that are more likely to receive insurance coverage. The result is that revenue streams become much more lucrative as a result. That&rsquo;s the primary reason to continue watching Viking Therapeutics.&nbsp;</p>



<h2>Matthews International (MATW)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/fr_firstindustrial1600-300x169.png" alt="Back View of the Head of the Project Holds Laptop and Discussing Product Details with Chief Engineer while They Walk Through Modern Factory., FR rents out these spaces in the U.S."><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Matthews International</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/matw-stock-quote/"><strong>MATW</strong></a></span>) is a boring industrial stock representing a company that produces memorials for the burial industry, industrial technologies, and brand solutions. Roughly <a href="https://www.matw.com/investors/news-events/press-releases/detail/247/matthews-international-reports-results-for-fiscal-2024">85% of revenues</a> are attributable to its memorialization segment which includes products such as headstones and cremation urns.</p>



<p>The company will be interesting to investors simply because it is <a href="https://stockanalysis.com/stocks/matw/forecast/">expected to more than double</a> from its current $28 share price. Matthews International is essentially flat from a fundamental perspective. Major metrics are down roughly 1%. The reason is that U.S. death rates have stabilized following the pandemic.&nbsp;</p>



<p>That logically begs the question of why MATW stock is so well regarded. Part of the answer can be found in the fact that the company paid down more than $27 million of debt during the most recent quarter. Otherwise, the company is also involved in the warehouse automation sector. The company has a chance to grow its revenues there while benefiting from the stability of its memorialization segment.</p>



<h2>Navitas Semiconductor (NVTS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/semiconductor1600e-300x169.jpg" alt="semiconductor stocks Close-up electronic circuit board. technology style concept. representing semiconductor stocks. top semiconductor stocks to buy now. semiconductor stocks"><div>Source: Shutterstock</div></div><p>Last on this list of stocks to buy is <strong>Navitas Semiconductor</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvts-stock-quote/"><strong>NVTS</strong></a></span>). It&rsquo;s a small semiconductor firm employing approximately 300 people and a penny stock in the chip sector.</p>



<p>Shares currently trade for under $5 but may not stay that way for long following strong earnings. Navitas Semiconductors revenues increased by 73% in the first quarter. The company manufactures gallium nitride power integrated circuits.&nbsp;</p>



<p>Those circuits are currently benefiting from strong adoption across growth sectors including <a href="https://www.globenewswire.com/news-release/2024/05/09/2879147/0/en/Navitas-Semiconductor-Announces-First-Quarter-2024-Financial-Results.html">mobile fast charging and AI data centers</a>. In other words, Navitas Semiconductor stock is a strong choice for investors seeking chip innovation at a cheap price.</p>



<p>The company anticipates continued rapid adoption of its gallium nitride systems which show particular strengths in relation to cost relative to silicon based solutions.</p>



<p>The company lists a host of applicable industries where its chips show particular strengths in the earnings report. Those industries also happen to be growing rapidly. Overall, Navitas Semiconductor is clearly an inexpensive chip manufacturer to watch moving forward.</p>



<p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines</em></a><em>.</em></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/double-up-delights-7-stocks-poised-to-soar-100-by-2025/">Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Contrarian investing has many risks. Despite this, some investors love to pick up stocks at 52-week lows. These companies show signs of being neglected by the market or are simply beaten down by bearish sentiment.&nbsp;</p>



<p>Investors sometimes like to find picks that can spring back up from an anticipated catalyst or even a seasonal event like Christmas. Who can blame them? If there are predictable ways to make money, why wouldn&rsquo;t an investor take advantage of it?&nbsp;</p>



<p>Since we&rsquo;re looking for stocks that&rsquo;ll likely do well around Christmas, I&rsquo;ll focus on companies with higher activity during the season &ndash; such as traveling and gift-giving. To come up with my list, I screened companies that fit the following criteria:</p>



<ul><li>Shipping, Travel, and Consumer Discretionary sectors</li>



<li>Stocks trading near its 52-week low based on percentage distance</li>



<li>Buy ratings from analysts</li>



<li>At least five analysts cover the stock</li>
</ul><p>I then sorted them based on how close the stocks were to their 52-week low and picked the bottom three. Doing so lets me focus on companies beaten by the market but still have promise.&nbsp;</p>



<h2>YETI Holdings (YETI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/yeti_yeti1600-300x169.jpg" alt="Several thermoses with the Yeti logo on them"><div>Source: David Tonelson / Shutterstock.com</div></div><p>If you&rsquo;re like me and love the outdoors, you may have heard of <strong>YETI Holdings</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/yeti-stock-quote/"><strong>YETI</strong></a>). The company designs, retails and distributes a variety of outdoor products that fall under three main categories.</p>



<ul><li><strong>Drinkware</strong> &ndash; includes its <a href="https://www.yeti.com/drinkware/can-insulators/colster-12oz.html#closeCSModal">colsters</a>, tumblers and pints</li>



<li><strong>Coolers &amp; Equipment</strong> &ndash; offers various types of coolers and water buckets</li>



<li><strong>Other</strong> &ndash; comprised of an array of gears and apparel that include a variety of outdoor goods</li>
</ul><p>YETI has previously acquired Mystery Ranch, another premium outdoor brand that offers durable backpacks, bags and accessories. This acquisition will enhance YETI&rsquo;s offerings for extreme users of load-bearing equipment.&nbsp;</p>



<p>The company ended fiscal year 2023 with <a href="https://s22.q4cdn.com/322452763/files/doc_financials/2023/ar/yeti-2023-annual-report.pdf">strong revenue growth</a> and a significant rise in earnings. Full-year revenue was $1.66 billion, a 3.98% increase from the previous year&rsquo;s $1.59 billion. Also, basic net income per share reached $1.96, improving 88.46% year-over-year (YOY).</p>



<p>Today, YETI stock trades at attractive levels, with <a href="https://www.nasdaq.com/market-activity/stocks/yeti/analyst-research">analyst buy ratings</a> and record-high gross margins exceeding 60%. YETI&rsquo;s 52-week low stock price is $33.88, which is 14.6% below the current share price. So, to pick some unpolished gems, check out YETI before it becomes expensive.</p>



<h2>Papa John&rsquo;s International (PZZA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/pzza-stock-300x169.jpg" alt="Billboard From Papa John's At Amsterdam East The Netherlands"><div>Source: DutchMen / Shutterstock.com</div></div><p>One of the biggest household pizza places in the U.S., <strong>Papa John&rsquo;s International</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pzza-stock-quote/"><strong>PZZA</strong></a></span>) operates its pizza stores and franchises its restaurants and delivery under the Papa John&rsquo;s name. The company operates in four main segments.</p>



<ul><li><strong>Company-owned restaurants </strong>&ndash; for U.S. domestic operations</li>



<li><strong>International operations</strong> &ndash; for franchise distributions outside of North America</li>



<li><strong>North America commissaries</strong> &ndash; operates its quality centers and dough production and distribution operations</li>



<li><strong>North American franchising</strong> &ndash; offers sales and support to its North American franchising operations</li>
</ul><p>The company boasts over 600+ company-owned locations and 5000+ franchised restaurants in more than 50 countries.</p>



<p>Papa John&rsquo;s Q1 of 2024 <a href="https://ir.papajohns.com/static-files/e1288027-1a23-43df-9a9b-6f035433c600">reports decreasing revenue</a> across company-owned and franchised restaurants in the U.S. and abroad. Still, some analysts see a potential for a recovery, judging from their <a href="https://www.nasdaq.com/market-activity/stocks/pzza/analyst-research">buy recommendations</a>. </p>



<h2>Chuy&rsquo;s Holdings (CHUY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/chuy_1600_a-300x169.jpg" alt="A photo of Chuy's (CHUY) sign on the outside or a restaurant."><div>Source: Blueee77/ShutterStock.com</div></div><p><strong>Chuy&rsquo;s Holdings</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/chuy-stock-quote/"><strong>CHUY</strong></a></span>) is a full-service restaurant in 16 states specializing in Tex-Mex-inspired dishes. The company&rsquo;s restaurants offer a variety of popular homemade sauces, like Boom-Boom, Hatch Green Chile and Creamy Jalapeno sauces.&nbsp;</p>



<p>Also, patrons will find a full-service bar in all Chuy&rsquo;s restaurants, where they can enjoy various beverage offerings.&nbsp;</p>



<p>Chuy&rsquo;s Holdings reported primarily negative numbers in Q1 of 2024. <a href="https://investor.chuys.com/news-events/press-releases/detail/172/chuys-holdings-inc-announces-first-quarter-2024">Revenue and net income were down</a>, though the company states that it was due to &ldquo;unfavorable weather conditions and the timing of Easter.&rdquo;&nbsp;</p>



<p>However, there&rsquo;s still some good news. The company is trading 1.57% away from its 52-week low, and CHUY stock even has a consensus <a href="https://www.nasdaq.com/market-activity/stocks/chuy/analyst-research">buy recommendation</a> from the 10 analysts covering the company. </p>



<p><em><em>On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a></em></p>
<div><p>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/christmas-comes-early-3-stocks-at-52-week-lows-set-to-double-by-years-end/">Christmas Comes Early: 3 Stocks at 52-Week Lows Set to Double by Year&#8217;s End</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Christmas Comes Early: 3 Stocks at 52-Week Lows Set to Double by Year's End

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are many must-own stocks beyond the mega-caps that aren&rsquo;t household names but have solid potential going forward. These stocks are using megatrends and tailwinds and have solid upside catalysts that could quickly propel them higher. Thus, I think it is worth having some exposure to these stocks, or you may miss out if these catalysts spark more excitement down the line.</p>



<p>What&rsquo;s more, these stocks are not just about future potential &ndash; they are delivering strong financial results today. Even if the stars don&rsquo;t fully align for them, I think these must-own stocks have enough cushion to still deliver gains.</p>



<p>Here are the seven must-own stocks:</p>



<h2>CRISPR Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks. Healthcare Stocks to Buy"><div>Source: metamorworks / Shutterstock</div></div><p><strong>CRISPR Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a>) is a company working to transform the treatment of serious health conditions through gene-editing research. With the recent approval of CASGEVY for sickle cell disease and beta-thalassemia in multiple countries and over 25 authorized treatment centers now active globally, I believe CRISPR is poised for significant growth. This tech can solve many diseases, and if the stars align, shareholders of CRSP could be in for enormous gains in the coming years.</p>



<p>The company&rsquo;s pipeline includes treatments for cancer, autoimmune disorders, diabetes, and heart disease, with multiple data updates expected in the next year to year and a half. Notably, CRISPR&rsquo;s proprietary nanoparticle delivery platform has enabled the addition of promising early research programs targeting uncontrolled high blood pressure and acute liver porphyria.</p>



<p>As of the end of March, the company maintains a strong balance sheet with approximately <a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-6" target="_blank">$2.1 billion available in cash</a>, cash equivalents, and marketable securities.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-89.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/05/chart-89.png" alt="Must-own stocks: CRSPR cash reserves"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>If analysts are right, this is more than enough to fund losses until it <a href="https://seekingalpha.com/symbol/CRSP/earnings/estimates" target="_blank">potentially turns profitable in 2027</a>.</p>



<h2>Rigetti Computing (RGTI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/quantum-computing-3-300x169.jpg" alt="A concept image showing a quantum computer with a matrix background; quantum computing. leading quantum stocks, Best Quantum Computing Stocks to Buy"><div>Source: Shutterstock</div></div><p><strong>Rigetti Computing</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgti-stock-quote/"><strong>RGTI</strong></a>) is working hard to develop new quantum computers and make quantum computing power available to everyone. Quantum computing could be the next big leap forward after artificial intelligence, with the potential to solve problems that are impossible now and create tremendous new opportunities. I&rsquo;m interested to see how far Rigetti has come, with their 9-qubit Ankaa system recently achieving a very impressive <a target="_blank" href="https://investors.rigetti.com/news-releases/news-release-details/rigetti-computing-reports-first-quarter-2024-financial-results">99.3% accuracy rate</a> for operations involving two quantum bits in the first three months of this year. They expect their upcoming 84-qubit Ankaa 3 system will keep an accuracy of over 99% by the end of 2024, followed by a 336-qubit Lyra system.</p>



<p>Rigetti is also growing the part of its business that delivers quantum computer processors (QPUs) to customers on-site. Recently, they provided a Novera QPU to Horizon Quantum Computing in Singapore. This follows earlier work with major U.S. research labs like Fermilab and the Air Force Research Lab. In April, Rigetti launched a new partnership program to support the development of on-premises quantum computing around the world. While still in the early days, Rigetti&rsquo;s technological progress and expanding customer relationships have made it a company with promising long-term potential for investors willing to accept some risk and uncertainty. With $3.1 million in quarterly revenue, up 39% from a year ago, Rigetti seems to be making steady strides and is certainly worth watching as this tech unfolds.</p>



<p>However, it is important to remember that cash could run out in a few years if it keeps losing money, but I think quantum computing breakthroughs could secure enough excitement by then to offset any cash crunch. Analysts also seem very bullish.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-90.png"><img width="1226" height="455" src="https://investorplace.com/wp-content/uploads/2024/05/chart-90.png" alt="RGTI upside potential"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><h2>Onto Innovation (ONTO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/semiconductor1600e-300x169.jpg" alt="semiconductor stocks Close-up electronic circuit board. technology style concept. representing semiconductor stocks. top semiconductor stocks to buy now. semiconductor stocks to sell"><div>Source: Shutterstock</div></div><p><strong>Onto Innovation</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/onto-stock-quote/"><strong>ONTO</strong></a>) is a company that provides process control for creating computer chips. They work with the semiconductor industry, which makes the tiny circuits used in all kinds of electronic devices. Onto is poised to benefit from the huge demand for high-performance memory and circuitry packaging needed for artificial intelligence devices. This <a href="https://finance.yahoo.com/news/onto-innovation-inc-nyse-onto-164838887.html" target="_blank">drove a solid 64% YOY increase in revenue</a> from specialty chip packaging last quarter. The company is also one of the most diversified geographically.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-91.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/05/chart-91.png" alt="Onto Innovation Segments"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>Onto&rsquo;s Dragonfly inspection system seems to be a key strength, with revenue jumping 30% over the previous period to support packaging for AI chips. They are also innovating ways to identify new flaws in extremely thin chip wafers used for multi-chip module packaging. With 69% of earnings now coming from the fast-growing specialty device and advanced packaging markets, Onto appears well-equipped to benefit from the rising needs of AI adoption.</p>



<p>While the company may not yet be on every investor&rsquo;s radar, I think Onto Innovation deserves a closer look, given its strong momentum and role in some of the most promising trends in chipmaking today. The future looks bright for this process control leader.</p>



<h2>AeroVironment (AVAV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/aerovironment-avav-1600-300x169.png" alt="The logo for AeroVironment (AVAV) is seen through a magnifying glass on the company's website."><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>AeroVironment</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avav-stock-quote/"><strong>AVAV</strong></a>) has built a name for itself by designing and manufacturing unmanned aircraft for both military and commercial applications. The company seems poised to benefit tremendously from the huge uptick in demand from governments all over the world who are increasing their drone budgets. In Q3 of FY2024, AeroVironment&rsquo;s <a href="https://www.investopedia.com/aerovironment-stock-jumps-as-defense-contractor-reports-strong-earnings-boosts-guidance-8604323" target="_blank">revenue jumped almost 40% YOY to $187 million</a>, largely driven by its Loitering Munition segment, which saw 140% growth in sales. Indeed, it is among the must-own stocks if you want to invest in defense.</p>



<p>Management is currently in deep discussions with the U.S. government regarding a large multi-year sole supplier contract for their Switchblade drone and is also engaging with over 20 interested countries hoping to purchase this platform. In fact, most of its sales are international.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-93.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/05/chart-93.png" alt="AeroVironment sales chart"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>I believe AeroVironment&rsquo;s cutting-edge drone technology makes them the first choice for the UAV revolution that is radically reshaping modern conflicts.</p>



<p>With backlog increasing 12% and investments in improving current solutions, AeroVironment appears well-prepared to meet the surging need.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-92.png"><img width="1026" height="364" src="https://investorplace.com/wp-content/uploads/2024/05/chart-92.png" alt="AeroVironment backlog"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>The stock remains a smart pick for investors wanting exposure to the booming drone industry trend, as analysts expect AeroVironment to deliver <a href="https://seekingalpha.com/symbol/AVAV/earnings/estimates" target="_blank">31% revenue growth in fiscal 2024</a> based on rising global defense budgets earmarked for drones.</p>



<h2>Hayward Holdings (HAYW)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/05/swimming-pool-summer-msn-300x165.jpg" alt=""><div>Source: Shutterstock</div></div><p><strong>Hayward Holding</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/hayw-stock-quote/"><strong>HAYW</strong></a>) makes swimming pool equipment and accessories. While not widely discussed on Wall Street, the company has a leading position in the growing commercial pool market. The commercial segment has continued to grow, whereas other segments have faced difficulties.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-94.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/05/chart-94.png" alt="Hayward Holdings commercial pool segment sales chart"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>According to <em>Global Market Insights</em> &ldquo;<a href="https://www.gminsights.com/industry-analysis/swimming-pools-and-spas-market#:~:text=Swimming%20Pools%20and%20Spas%20Market%20size%20was%20valued%20at%20over,7.5%25%20between%202024%20%26%202032." target="_blank">Swimming Pools and Spas Market size was valued at over USD 2 billion in 2023 and is anticipated to grow at a CAGR of over 7.5% between 2024 &amp; 2032.</a>&ldquo;</p>



<p>The company&rsquo;s <a target="_blank" href="https://seekingalpha.com/article/4689357-hayward-holdings-inc-hayw-q1-2024-earnings-call-transcript">sales of commercial pool systems in North America surged double-digits</a> in the first quarter, continuing a years-long trend fueled by more travel and hotel construction since the pandemic.</p>



<p>Despite broader economic challenges, Hayward delivered impressive first quarter results with revenue up 1%, gross profit margins expanding 260 basis points to a record 49.2%, and strong cash flow. Management is skillfully navigating near-term demand uncertainty by consolidating their European facilities while introducing new innovative products to gain more market share.</p>



<p>Now that the inventory replenishment period is mostly over and early customer discounts have expired, I expect Hayward&rsquo;s price increases will have a fuller impact on financials in the coming periods. This pricing power combined with Hayward&rsquo;s strengthening profits and cash generation makes the stock look undervalued at current price levels in my view. As leisure spending keeps rebounding, Hayward seems well-positioned to deliver gains for investors. As such, I think it is one of the best must-own stocks for the pool market exposure.</p>



<h2>Universal Display Corporation (OLED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/oled-stock-1-300x169.jpg" alt="OLED screen representing OLED stock"><div>Source: Daniel Pieterson / Shutterstock.com</div></div><p><strong>Universal Display</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/oled-stock-quote/"><strong>OLED</strong></a>) is a leading developer of OLED technologies for the display and lighting markets. Their numbers show that more and more industries are embracing OLED due to its superior performance and flexible design options. You may have recently heard about the new iPad M4 and its dual OLED technology. I think many more devices could start using it.</p>



<p>I believe the growing OLED information technology market presents a huge growth opportunity for Universal Display. Research shows OLED personal computer shipments are projected to skyrocket from <a href="https://finance.yahoo.com/news/q1-2024-universal-display-corp-103739646.html#:~:text=This%20translates%20into%20total%20mobile,growth%20is%20new%20OLED%20capacity." target="_blank">7.1 million units in 2023 to an incredible 17.2 million units in 2024</a> and to a staggering 72.3 million in 2028. This rapid expansion is fueled by major players like Samsung Display and BOE, which have significantly increased their OLED IT manufacturing capabilities. Thus, I think OLED is definitely one of the must-own stocks if you want to have exposure to this tech.</p>



<p>What&rsquo;s more, the rising popularity of OLED in smartphones, foldable devices, and televisions further strengthens Universal Display&rsquo;s long-term potential for success. As a top OLED innovator, they are well-positioned to benefit from these large shifts happening in the display world. The margins on its sales are excellent, too.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-95.png"><img width="1226" height="796" src="https://investorplace.com/wp-content/uploads/2024/05/chart-95.png" alt="OLED margins"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>With Universal Display increasing their projected full-year revenue guidance to an impressive $635-$675 million range, I am getting more and more optimistic about the company&rsquo;s future potential.</p>



<h2>YETI Holdings (YETI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/yeti_yeti1600-300x169.jpg" alt="Several thermoses with the Yeti logo on them"><div>Source: David Tonelson / Shutterstock.com</div></div><p><strong>YETI</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/yeti-stock-quote/"><strong>YETI</strong></a>) is a company that sells outdoor products. It posted <a href="https://www.xm.com/research/markets/allNews/reuters/yeti-holdings-jumps-after-q1-results-beat-53834465" target="_blank">solid Q1 results</a>, with double-digit sales increases in all of its major categories like wholesale, direct-to-consumer, coolers and equipment, and drinkware. This positions them well to capitalize further during their key summer season.</p>



<p>I remain optimistic about the potential for expanding into new international markets &ndash; their overseas sales increased over 30% YOY and now comprise approximately 19% of total revenue. As interest in outdoor lifestyle products continues to grow globally, I believe this trend will serve as a tailwind for YETI&rsquo;s business.</p>



<p>Encouragingly, YETI has successfully boosted profit margins substantially. Gross margins rose more than 450 basis points thanks to improved freight management. This translated to nearly a 440 basis point increase in adjusted operating margins as well.</p>



<p>YETI seems well-positioned for ongoing success in 2024.</p>



<div><a href="https://investorplace.com/wp-content/uploads/2024/05/chart-96.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/05/chart-96.png" alt="YETI Holdings EPS estimates"><br>Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><p>I maintain a bullish outlook as this company beat EPS estimates by 39% and has significant room for recovery in the coming years with earnings expansion.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-stocks-you-havent-heard-of-that-everyone-should-own/">7 Stocks You Haven&#8217;t Heard of (That EVERYONE Should Own)</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Stocks You Haven't Heard of (That EVERYONE Should Own)

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Yeti Holdings (YETI – Research Report), eBay (EBAY – Resea...

Analysts Offer Insights on Consumer Cyclical Companies: Yeti Holdings (YETI), eBay (EBAY) and XCel Brands (XELB)

There's a lot to be optimistic about in the Consumer Cyclical sector as 3 analysts just weighed in on Best Buy Co (BBY – Research Report), Dollaram...

Analysts Offer Insights on Consumer Cyclical Companies: Best Buy Co (BBY), Dollarama (OtherDLMAF) and Yeti Holdings (YETI)

YETI Holdings: Solid Q1 Results Led By International Growth

YETI Holdings: With Return To Solid Growth And Consistent Margin Expansion, Some Clouds Have Lifted (Upgrade)

In a report released yesterday, Randal Konik from Jefferies maintained a Buy rating on Yeti Holdings (YETI – Research Report), with a price target ...

Buy Rating on Yeti Holdings: Strategic Product Expansion and Attractive Valuation

Jefferies analyst Randal Konik maintained a Buy rating on Yeti Holdings (YETI – Research Report) today and set a price target of $55.00. The compan...

Jefferies Sticks to Their Buy Rating for Yeti Holdings (YETI)

ARWR

AVAV

BERY

CHUY

CRSP

DLMAF

EBAY

HAYW

JOBY

MATW

NVCR

NVTS

OLED

ONTO

PZZA

RGTI

VKTX

XELB

Press Releases

YETI Appoints Elizabeth Axelrod and Robert Katz to Board of Directors

YETI Holdings, Inc. Announces Reporting Date for Fourth Quarter and Fiscal 2023 Financial Results

YETI® Acquires MYSTERY RANCH®

YETI Reports Fourth Quarter and Fiscal Year 2023 Results

SmartRent Names Alison Dean to Board of Directors

YETI Holdings, Inc. Announces Reporting Date for First Quarter Fiscal 2024 Financial Results

YETI Reports First Quarter 2024 Results

Athleisure and Luxury Fuse to Lead Consumer Trends

Athleisure and Luxury Fuse to Lead Consumer Trends (AXIL, LULU, NKE, YETI)

YETI Holdings, Inc. Announces Reporting Date for Second Quarter Fiscal 2024 Financial Results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

YETI Holdings

YETI Holdings (YETI) Forecast

YETI Holdings (NYSE:YETI) Stock, Quote.Headers.trade-ideas